Cannabidiol in Patients with Treatment-Resistant Epilepsy

Prisca R. Bauer,Josemir W. Sander

DOI: https://doi.org/10.1016/s1474-4422(16)00118-6

2016-01-01

Abstract:We read with interest the results reported by Orrin Devinsky and colleagues1Devinsky O Marsh E Friedman D et al.Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.Lancet Neurol. 2016; 15: 270-278Summary Full Text Full Text PDF PubMed Scopus (589) Google Scholar of an open-label trial of cannabidiol in people with refractory epilepsy. This is a sensitive topic for many, as there are high expectations for cannabidiol as a potential therapy for epilepsy. Some of these expectations have been fuelled by the media. Unlike other compounds which are conventionally trialled away from the public eye, cannabidiol is already legally available in some countries. Promising case reports2Maa E Figi P The case for medical marijuana in epilepsy.Epilepsia. 2014; 55: 783-786Crossref PubMed Scopus (179) Google Scholar have encouraged demand for cannabidiol, however, little is known about its safety and efficacy, making the study by Devinsky and colleagues particularly timely. An overall seizure reduction of almost 50% compared with baseline is reported in this study. The analysis suggests that about a third of participants had an increased seizure frequency during the treatment period, and another third had less than 50% seizure reduction. Patients often start or switch antiepileptic drugs at times of an exacerbation of seizure frequency. Figure 3 seems to show a regression to the mean that can partly be attributed to the natural course of the condition, and which is inadequately controlled for by the short baseline period of this study. A baseline period of 4 weeks seems too short, especially as the lowest seizure frequency was 11 motor seizures per month. A natural variation in seizure frequency of one or two seizures per month could explain a 10–20% change either way. Adverse events are reported in 78% and serious adverse events in 30% of the participants in the 12 week treatment period. The authors conclude that “cannabidiol has an adequate safety profile”. Compared with other antiepileptic drugs in refractory epilepsy, the number of serious adverse events reported seems high.3Brodie MJ Lerche H Gil-Nagel A et al.RESTORE 2 Study GroupEfficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy.Neurology. 2010; 75: 1817-1824Crossref PubMed Scopus (178) Google Scholar This high frequency might be explained by epilepsy severity in this population, but such an interpretation cannot be assessed with the design of this study. What this study does show is that, contrary to what many hope, cannabidiol is probably not the magic bullet for severe childhood epilepsy. Properly randomised controlled trials are urgently needed to assess the safety profile and efficacy of cannabidiol are similar to those of other antiepileptic drugs, or worse. JWS has been consulted by and received fees for lectures from GSK, Lunbeck, Teva, Eisai, and UCB Pharma. PRB declares no competing interests. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trialOur findings suggest that cannabidiol might reduce seizure frequency and might have an adequate safety profile in children and young adults with highly treatment-resistant epilepsy. Randomised controlled trials are warranted to characterise the safety profile and true efficacy of this compound. Full-Text PDF Cannabidiol in patients with treatment-resistant epilepsy – Authors' replyWe appreciate the thoughtful comments by Prisca Bauer and Josemir Sander and David Mandelbaum about our study.1 Both letters emphasise the limits of an open-label study in which the compound has received considerable media attention. We fully agree with these reservations and acknowledge that only a randomised, double-blind, placebo-controlled study can inform about the safety and efficacy of cannabidiol, or any other compound. Our conservatism is clear by the concluding sentence of the summary: “randomised controlled trials are warranted to characterise the safety profile and true efficacy of this compound”. Full-Text PDF